

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 29, 2021**

**OVID THERAPEUTICS INC.**

(Exact name of Registrant as Specified in Its Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-38085**  
(Commission File Number)

**46-5270895**  
(IRS Employer  
Identification No.)

**1460 Broadway, Suite 15044**  
**New York, New York**  
(Address of Principal Executive Offices)

10036  
(Zip Code)

**Registrant's Telephone Number, Including Area Code: 646-661-7661**

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001 per share	OVID	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 1.02 Termination of a Material Definitive Agreement**

Ovid Therapeutics Inc. (the “Company” or “we” or “our”) received Notice of Termination dated March 29, 2021 of the Collaboration and License Agreement (the “Agreement”), dated July 9, 2020, by and between the Company and Angelini Pharma Rare Diseases AG (“Angelini”). Termination of the Agreement will be effective on September 30, 2021, or such earlier date as may be mutually agreed to between the Company and Angelini. Following termination of the Agreement, the Company will be released from its performance obligations and will not be entitled to any future milestone payments under the Agreement. A summary of the material terms and conditions of the Agreement is qualified in its entirety by reference to the full text of the Agreement, a copy of which was filed as Exhibit 10.25 to the Company’s Annual Report on Form 10-K for the fiscal year ending December 31, 2020 filed with the Securities and Exchange Commission on March 15, 2021.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**OVID THERAPEUTICS INC.**

By: /s/ Thomas M. Perone  
Thomas M. Perone  
General Counsel & Corporate Secretary

Dated: April 1, 2021